

# **HeiQ PLC**

# Results 2022 Half Year Results 2023

Traded at:

XLON: HEIQ

ISIN: GB00BN2CJ299



October 31, 2023

## **Disclaimer**



The distribution of this Presentation in jurisdictions other than the UK may be restricted by law and persons into whose possession this document comes should inform themselves about and observe any relevant restrictions. In particular, this document may not be published or distributed, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.

This Presentation made by HeiQ (or of a new holdco inserted for the purposes of admission to trading) does not constitute an offer of, or an invitation by or on behalf of the Company or anyone else to purchase or subscribe for, any securities of or investment in the Company in any circumstances. You are reminded that any subscription for securities or investment in any offering may be made solely on the basis of your own due diligence, investigations and assessment and solely on the basis of the information contained in the admission document in its final form and no reliance may be placed on the information contained in this document. This Presentation and the information contained within it are strictly confidential to the recipient, may not be distributed to any other person, and may not be further disclosed, copied or reproduced in any form, in whole or in part. Failure to comply with these restrictions may constitute a violation of applicable securities laws.

The information contained in this Presentation is for background purposes only, has not been independently verified by the Company nor any of the Company's directors, officers, shareholders, advisors or representatives. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. Save in the case of fraud, neither the Company nor any of its directors, officers, shareholders, advisors or representatives shall have any liability whatsoever for any loss arising from any use of this Presentation or its contents or otherwise arising in connection with this Presentation. By accepting this Presentation you agree, upon request, to return promptly all material received from the Company without retaining any copies.

This Presentation is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000. This Presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity in any jurisdiction. In addition, this Presentation does not constitute a recommendation by the Company or any other person regarding any securities of, or an investment in, the Company. Neither this document nor any part thereof, nor the fact of its distribution, shall form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This Presentation does not take into account the investment objectives, financial situation or particular needs of any particular investor, and it does not purport to be comprehensive or to contain all of the information that a prospective investor may desire or require in investigating the Company or an investment in the Company. Accordingly, each prospective investor should conduct its own due diligence in connection with any potential investment in the Company and seek the advice of its own professional advisors. Prospective investors must not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and must make their own assessments concerning these and other consequences of any investment in the Company, including the merits of investment and the risks.

This Presentation is directed only at persons who (i) are "qualified investors" within the meaning of Article 2(1)(e) of Directive 2003/71/EC (as amended) and any relevant implementing measures and (ii) are outside the United Kingdom, and/or (iii) have professional experience in matters relating to investments who fall within the definition of "investment professionals" contained in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"), or are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this Presentation or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This Presentation may include statements that are, or may be deemed to be, "forward-looking statements". Any forward-looking statements in this Presentation reflect the Company's current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this Presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Presentation.

Cavendish Securities plc ("Cavendish"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting for the Company and for no-one else in connection with the contents of this presentation and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Cavendish, or for providing advice in relation to the contents of this presentation or any matters referred to herein. This document has not been approved by Cavendish for the purposes of Section 21 of the Financial Services and Markets Act 2000.

# **Agenda**



Looking back 2022 & H1 2023

• 0 0



Measures taken

• • 0



Focus, Ventures & Outlook

• •





# 2022 (H2) & 2023 - two equally challenging years



## **Challenges as of H2 2022**

- Market demand: Overstocking and high inventories across our customer base, coupled with increasing inflation & interest rate increase, led to a significant decrease in consumer demand with rippling amplified effects across the value chain (bull-whip-effect)
- End of the year overstocking by brands caused a global Q4 2022 purchasing-stop cliff in the textile industry (largest market for HeiQ)
- General slow-down in markets caused businesses acquired in 2022 to be significantly delayed in achieving their business plans
- Global CRM & ERP harmonization project started in 2022, to integrate internal control system & financial reporting system.
- Change of auditor late in the year 2022, worsening market conditions and still insufficient internal control systems after high-growth phase with multiple acquisition in recent years caused the auditor to increase their audit risk assessment and review levels



## **How it impacted HeiQ**

- Missing revenues and contribution margin from commercial activities no longer provided cash for financing of innovations & ventures leading to a significant cash burn to maintain ventures alive
- The sudden decrease in demand caused an overstocking of certain customer & market specific inventory items which therefore had to been written off to a large part
- Significant write-off of goodwill paid for the different businesses following inability to materialize their forecast following the downturn
- Switch at the same time than market disruption, caused a 10 monthlong audit, tripled our auditing costs & led to our shares to be suspended from trading for 6 month
- Publication of audited accounts 2022 was significantly delayed.

# **HeiQ growth history**







\*2022 Gross margin significantly reduced by inventory allowance





Revenue decreased due to low demand across industry

Gross margins down driven by allowances on inventory




Significant impairments of Goodwill from acquisitions



SG&A costs increase driven by acquisitions and investments in innovation and audit costs

US\$ '000	H1 2023	H1 2022		2022	2021	
		restated			restated	
Revenue	20'500	27'558	-26%	47'202	55'419	-15%
Gross profit	8'390	11'431	-27%	13'457	25'397	-47%
Gross margin	41%	41%		29%	46%	
SG&A	-14'263	-14'016	-2%	-30'969	-24'680	-25%
Impairment losses - total	-	-		-12'381	-2'454	
Other Income/(expenses) - net	-129	1'013	-113%	648	383	69%
Operating profit	-6'002	-1'572	-282%	-29'245	-1'354	-2060%
Finance income/(costs) - net	-379	-82	-362%	-590	-35	-1586%
Income before taxation	-6'381	-1'654	-286%	-29'835	-1'389	-2048%
Taxation	-146	-254	43%	21	16	31%
Income after taxation	-6'527	-1'908	-242%	-29'814	-1'373	-2071%
Adj. EBITDA	-3'612	721	-601%	-12'174	4'545	-368%



**47.2 55.4** 2022 2021



**28.5**\* **45.8** 2022 2021

 2022 Gross margin significantly reduced by one-time inventory allowance



**-12.2 4.5** 2022 2021



# **Statement of Financial Position**

US\$ '000	H1 2023	2022	2021
			restated
Intangible assets	21'672	20'442	30'773
Non-current assets	39'732	38'738	47'282
Inventories	14'406	13'168	13'770
Trade receivables	8'256	6'487	14'656
Other receivables and prepayments	4'231	4'262	3'876
Cash and cash equivalents	7'274	8'488	14'560
Current assets	34'167	32'405	46'862
Total assets	73'899	71'143	94'144
Total equity	34'745	40'339	59'535
Total equity Long-term borrowings	<b>34'745</b> 1'866	<b>40'339</b> 1'445	<b>59'535</b> 1'605
Long-term borrowings	1'866	1'445	1'605
Long-term borrowings  Total non-current liabilities	1'866 <b>16'064</b>	1'445 13'970	1'605 <b>13'766</b>
Long-term borrowings  Total non-current liabilities  Short-term borrowings	1'866 <b>16'064</b> 7'471	1'445 <b>13'970</b> 2'893	1'605 <b>13'766</b> 1'157
Long-term borrowings  Total non-current liabilities  Short-term borrowings  Total current liabilities	1'866 <b>16'064</b> 7'471 <b>23'090</b>	1'445 13'970 2'893 16'834	1'605 13'766 1'157 20'843
Long-term borrowings  Total non-current liabilities  Short-term borrowings  Total current liabilities  Total liabilities	1'866 16'064 7'471 23'090 39'154	1'445 13'970 2'893 16'834 30'804	1'605 13'766 1'157 20'843 34'609

Significant decrease in Total assets following Goodwill impairments and derecognition of revenues/receivables

Missing contribution margins lead to significant decrease in cash and net debt position

Uncommitted short-term credit lines
(overdrafts and fix cash advances)



# **Cashflow & Liquidity**

#### **Cashflow Statement**

US\$ '000		2022	2021
			restated
Net cash generated from/(used in) operating activities	-4'799	-2'459	3'408
Net cash from /used in investing activities	-427	-8'750	-12'664
Net cash from /used in financing activities	3'902	5'845	-1'269
Net (decrease) /increase in cash	-1'324	-5'364	-10'255
Cash balance (end of period)	7'274	8'488	14'560



Significant cash burn in 2022 / H1 2023 due to missing cash contribution from commercial businesses while build-up of ventures continued



Corrective measures taken in late 2022 / H1 2023 to reduce cost base

(becoming effective in course of H2 2023)



Funding of Ventures through capital raise / project financing on subsidiary level required

#### **Current credit facilities**

	Oct '23
Maturity date	CHF '000
1month-rolling (Nov 27, '23)	4'500
June 17, '24	800
Sept 30, '24	1'000
Total drawn amounts	6'300
Total facility	9'000



Uncommitted credit facilities seen as risk due to shortterm re-financing requirement in case of termination

(total credit lines CHF9 million - used CHF6.3 million)



No indication from banks that credit facilities are at risk of being terminated



Discussion to restructure uncommitted facilities into committed facilities initiated



# Measures taken




# Reorganized "Agile" to drive growth and create long-term value

# In distressed markets more agility & situational awareness is required with decision making power by teams on the frontline

 Focused small teams with a clear mission, target and responsibilities

**Objective: Enhance Agility** 

- Enable venture project financing on "subsidiary" level including industry partner co-investments to support and accelerate value creation
- Lean Group (support) Functions allocation of activities and costs as much as possible into Growth and Venture Units







# Focus III

- Re-organized commercial business into three agile & dedicated business units with own objectives, CEO's teams & P&L
  - Textiles & Floorings
     CEO Mike Abbott
     HQ USA
  - 2. Life Sciences CEO Dr. Robin Temmerman HQ Belgium
  - 3. Antimicrobials
    CEO Tom Ellefsen
    HQ Thailand
- Focused on commercialized innovations and mature, sustainable and future-proof innovations such as HeiQ Allergen Tech, HeiQ Synbio, HeiQ Mint and HeiQ Smart Temp

## Restructre | | ==

- · Relocation of costs
  - >20FTE's from high-cost GHQ Switzerland replaced in our lower cost Portugal Hub without losing capabilities.
  - Significant manufacturing operations transferred to our lower energy cost locations in USA
  - FTE costs from other services transferred to financial services (12 FTE team now)
- Restructured commercial team for key market China – lead now with GM Mr. Robert Liu

Reduction of overall annualized SG&A costs for Growth & Support Units by 15% becoming effective in course of H2 2023

## Finance Ventures III

- Financing of main Venture Innovation HeiQ AeoniQ in subsidiary directly (partner investments, project financing) to ensure continuing value creation
  - MAS Investment of 1.5M USD into HeiQ AeoniQ in June 2023





# Focus Q4 2023 / 2024

## **Venture Units**

- Funding of Venture innovations at project /subsidiary level
  - Close Series A financing round for scale-up of HeiQ AeoniQ 3,000t/a capacity fiber plant. Total project costs 70M €
  - Acquire further grants and customer paid application developments
- System & Processes: Strengthen Internal Control System

## **Growth Units**

- Return to positive cash generation for all Growth Units
  - Reduced cost for best-selling products by backwards integration
  - Win market share with new innovations launched
- Liquidity management: NWC optimization
- System & Processes: Strengthen Internal Control System

# Support Units

- Financing facilities: Transform uncommitted, short-term financing facilities to longer-term, committed facilities
- System & Processes
  - Strengthen Internal Control System
  - Complete group IT integration on Odoo ERP/CRM system
- Ensure timely year end reporting for 2023
- Complement Board expertise on ESG & ICS





## **Growth Units - Current market conditions**

#### **Textile & Floorings**

- Textile Brands suffer lower sales to consumers. Only discounters grow.
   Overstocking is still hampering the value chain. Payment terms are extended. Our innovations manage to win us new programs to grow
- Our Floorings offering is suffering by building industry crisis & shift from carpet to tiles. Our backwards integration enables us to gain market share and margins
- Our Industrial Chemicals sales in the US have more than doubled and are on an upwards trend as the US is reindustrializing

#### **Life Sciences**

- We are divesting form our medical masks operations in Spain following reduced postpandemic sales
- With HeiQ Synbio we have successfully established probiotic cleaners for hospitals and anchored them in the new EU detergent regulation. We expect a switch in the industry towards our technology in 2024 with corresponding growth of our sales
- We have successfully integrated our new cosmetic grade manufacturing plant into our re-audited ISO 9001 standard. We expect to serve cosmetic brands as OEM supplier in 2024

#### **Antimicrobials**

- FMCG Brands suffer lower sales to consumers. Only discounters grow. Overstocking is still hampering the value chain. Payment terms are extended.
   Our innovations manage to win us new programs to grow
- We have successfully launched HeiQ Chill innovation, a cooling technology for masterbatchers, to first implementers
- Anta, a large Chinese sport apparel & footwear brand has adopted innovative HeiQ Life Natural antimicrobials in their kids line



# **Venture Units – project status update**



#### **HeiQ AeoniQ**

Worlds first climate positive cellulose filament fiber, capable to replace polyester

#### Project phase:

Industrialization

#### Next milestone:

\$20M series A for 3'000 tons manufacturing plant in Portugal

#### Time to market: on market

**USP:** Replaces the \$135bn p.a. polyester fiber industry

#### **HeiQ ECOS**

Silver Nanowire tech for lowE Coatings (transparent, conductive, heat-reflecting), & stealth effets

#### Project phase:

**Application Development** 

#### Next milestone:

Agreements with defense, greenhouse, window partner

#### Time to market: on market

USP: Reduces energy costs of households by ca. 30%, improves efficiency of Greenhouses by ca. 30%

#### **HeiQ GrapheneX**

Highly porous graphene membrane for solid state batteries & electronic vents

#### Project phase:

Pilot commercialization plant scale-up

#### Next milestone:

Sign JDA with industry partner for first application

#### Time to market: <2 years

USP: Enables lighter solid state lithium batteries at double charge and 10 times faster recharge

#### **HeiQ BacCell**

Agri-waste based bacterial cellulose as superior feedstock for fibers, packaging, medical, cosmetic and food industries

#### Project phase:

Pilot plant scale up

#### Next milestone:

Proof of concept of dynamic industrial reactor


#### Time to market: <2 years

USP: Circular waste- based superior feedstock for cellulose fibers, strengthens cellulosic packaging materials significantly



# **HeiQ** – invest in impact





# Differentiate. Innovate.

# 9

#### **Switzerland**

Schlieren (Zurich)

HeiQ Materials AG
Operational headquarters
R&D/Testing/Production

#### **Australia**

Geelong

HeiQ PTY
R&D/Production

#### **Austria**

Herzogenburg

HeiQ GmbH R&D/Sales

## **Belgium**

Ultimate parent

Lommel

UK

London HeiQ plc

HeiQ Chrisal NV R&D/Production

#### **Germany**

Regensburg

HeiQ RAS AG R&D/Sales

#### **Greater China**

Shanghai

HeiQ Materials Company Limited Warehouse/Testing/Sales

### Taoyuan City/Taiwan

HeiQ Company Ltd / HX Company Ltd Sales/Production

### Japan

**Tokyo** Sales

## **Portugal**

Moreira da Maia

HeiQ Iberia Unipessoal Lda R&D/Sales

## **Spain**

Pizarra (Málaga)

HeiQ Medica SL R&D/Production/Sales

## **Thailand**

Bangkok

HeiQ Life
R&D/Production/Sales

#### USA

Concord & Calhoun

HeiQ ChemTex Inc. *R&D/Production/Sales* 

#### Follow us:













